ARTICLE | Product Development
Away from ASCO, handful of biotechs eye follow-ons or regularly submissions backed by new data
By BioCentury Staff
June 4, 2024 11:40 PM UTC
With most attention focused on the American Society of Clinical Oncology meeting, a handful of other biotechs had readouts — most of them positive — outside the cancer arena over the past few days.
Investor demand for obesity plays remains sky-high even if the data don’t appear to be best in class. That’s the message the market appeared to deliver on Monday after Structure Therapeutics Inc. (NASDAQ:GPCR) climbed 54% after reporting data for GSBR-1290 with good efficacy but, as of yet, a poor tolerability profile…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652604/clinical-report-obesity-win-for-structure-plus-upbeat-data-for-annexon-agios-arrowhead-ultragenyx-intellia